ReviewNature reviews. Endocrinology2025
Early-onset colorectal cancer as an emerging disease of metabolic dysregulation.
Review in Nature reviews. Endocrinology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Early-onset colorectal cancer is associated with metabolic disorders: a systematic review and meta-analysis.European journal of epidemiology · 2026Pooled it
- Gut microbiota and diet in colorectal cancer: Converging determinants of carcinogenesis.Gut microbes · 2026Review
- Shaping the future of early-onset colorectal cancer prevention.Nature reviews. Cancer · 2026Review
- Early-Onset Colorectal Cancer: Clinical and Molecular Features with Emerging Insights from Comprehensive Genomic Profiling.Oncology and therapy · 2026Review
- Early-Onset Colorectal Cancer: From Epidemiologic Shift to Life-Course Carcinogenesis and Age-Attuned Care.Current oncology reports · 2026Review
- Polygenic risk scores, adiposity, and disease transition in type 2 diabetes and colorectal cancer comorbidity: a population-based Chinese cohort study.BMC cancer · 2026Observational
- Programmable two-dimensional CoOOH nanosheets with a hybridization chain reaction amplification system for label-free fluorescent detection of miRNA-205 in colorectal cancer.Mikrochimica acta · 2026Article
- Biological aging and generational shifts in early-onset cancer risk.Nature medicine · 2026Article
- CCL2: A Pro-Inflammatory Driver and Candidate Diagnostic Biomarker in Colorectal Cancer Patients.International journal of molecular sciences · 2026Article
- Cartilage Oligomeric Matrix Protein (COMP) Correlates with Disease Progression, Selected Immune Checkpoint Molecules and SIGLEC9 in Colorectal Cancer.International journal of molecular sciences · 2026Article
- Metabolic and Laboratory Biomarkers in Early-Onset Versus Late-Onset Colorectal Cancer: A Case-Control Study.Cancers · 2026Article
- Review
- Late effects among colorectal cancer survivors ≥5 years after diagnosis-a systematic scoping review.JNCI cancer spectrum · 2026Article
- Accelerating discovery of cancer causes for prevention in the era of rising early-onset cancers.Cell · 2026Review
- Targeting phase separation: a new strategy to disrupt the stromal-immune axis in colorectal cancer.Cell communication and signaling : CCS · 2026Review
- Temporal patterns in mortality from type 2 diabetes and digestive system cancers-an epidemiological analysis of the US population from 1999 to 2023.BMC public health · 2026Article
- Why Is Colorectal Cancer Occurring Earlier? Metabolic Dysfunction, Underrecognized Carcinogens, and Emerging Controversies.Current obesity reports · 2026Review
- Review
- Review
- Emerging nano-immunotherapeutic strategies achieve metastatic colorectal cancer precision therapy.Journal of nanobiotechnology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Colorectal cancer (CRC) is one of the most common malignancies and the second leading cause of cancer-related death worldwide. Early-onset CRC (EOCRC), diagnosed in adults under the age of 50 years, has emerged as a pressing public health concern owing to its alarming rise in incidence since the 1990s. This trend, observed in the USA and at least eight other high-income countries, starkly contrasts with the declining incidence rates of late-onset CRC (age 50 years and above), largely attributed to early disease detection and lifestyle changes. Concurrent with the rising number of cases of EOCRC, the burden of metabolic diseases, particularly obesity and type 2 diabetes mellitus (T2DM), has surged among young populations. Despite well-documented links between metabolic dysfunction and late-onset CRC, understanding the precise role of obesity and T2DM in the pathogenesis of EOCRC remains in its infancy. This narrative Review synthesizes evidence on the relationship of obesity and T2DM with EOCRC, focusing on pathophysiological mechanisms and the mediating roles of diet and lifestyle factors. It also discusses potential clinical and public health strategies to address obesity and T2DM for EOCRC prevention, highlighting knowledge gaps and future research directions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.